HCV-induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response.
Fiche publication
Date publication
mars 2019
Journal
Gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas, Dr DAVIDSON Irwin, Dr HABERSETZER François, Dr LUPBERGER Joachim, Pr PESSAUX Patrick, Dr CROUCHET Emilie
Tous les auteurs :
Hamdane N, Jühling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, Schmidl C, Bock C, Schuster C, Lupberger J, Habersetzer F, Doffoël M, Piardi T, Sommacale D, Imamura M, Uchida T, Ohdan H, Aikata H, Chayama K, Boldanova T, Pessaux P, Fuchs BC, Hoshida Y, Zeisel MB, Duong FHT, Baumert TF
Lien Pubmed
Résumé
Chronic hepatitis C virus (HCV) infection is an important risk factor for hepatocellular carcinoma (HCC). Despite effective antiviral therapies, the risk for HCC is reduced but not eliminated following a sustained virologic response (SVR) to direct-acting antiviral (DAA) agents, and risk is higher in patients with advanced fibrosis. We investigated HCV-induced epigenetic alterations that might affect risk for HCC after DAA treatment in patients and mice with humanized livers.
Mots clés
Biomarker, Sox9, biopsy, chemoprevention
Référence
Gastroenterology. 2019 Mar 2;: